Other · Immune activation, directed at lipopolysaccharide (LPS) · developed by Immuron
IMM-124E is a hyper-immune bovine colostrum powder enriched with anti-LPS antibodies. It is administered orally and is being studied in nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and alcoholic hepatitis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03042767 | Phase 2 | Nonalcoholic Fatty Liver Disease (NAFLD) | Completed | IMRN |
| NCT01968382 | Phase 2 | Hepatitis, Alcoholic | Completed | IMRN |
| NCT01466894 | Phase 2 | Nonalcoholic Steatohepatitis | Withdrawn | IMRN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hepatitis, AlcoholicNonalcoholic Fatty Liver Disease (NAFLD)Nonalcoholic Steatohepatitis
Updated Oct 3, 2026. Something wrong or missing? Report it on the IMRN page.
See IMRN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IMRN catalysts and pipeline →